Immunoglobulins IgG1, IgM and IgA: A synergistic team influencing survival in sepsis

Journal of Internal Medicine

Volumn 276, Issue 4, 2014, Pages 404-412

  Bermejo Martin J F ^a   Rodriguez Fernandez, A ^a   Herran Monge R ^b   Andaluz Ojeda, D ^a   Muriel Bombin A ^b   Merino, P ^b   Garcia Garcia M M ^b   Citores, R ^a   Gandia F ^a   Almansa, R ^a   Blanco, J ^b,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Immunoglobulin; Isotypes; Mortality; Sepsis; Shock

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEPSIS; SEPTIC SHOCK; SURVIVAL; SURVIVAL TIME; BLOOD; CLINICAL TRIAL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; KAPLAN MEIER METHOD; MULTICENTER STUDY; PROGNOSIS; REGRESSION ANALYSIS;

AGED; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTENSIVE CARE UNITS; KAPLAN-MEIER ESTIMATE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SEPSIS; SHOCK, SEPTIC;

EID: 84922393941     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12265     Document Type: Article

References (20)

1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369: 840-51.
2. Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. BMJ 2007; 335: 879-83.
3. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008; 14: 64-78.
4. Venet F, Gebeile R, Bancel J et al. Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients. Int Immunopharmacol 2011; 11: 2086-90.
5. Andaluz-Ojeda D, Iglesias V, Bobillo F et al. Early natural killer cell counts in blood predict mortality in severe sepsis. Crit Care 2011; 15: R243.
6. Taccone FS, Stordeur P, De Backer D, Creteur J, Vincent J-L. Gamma-globulin levels in patients with community-acquired septic shock. Shock 2009; 32: 379-85.
7. Tamayo E, Fernández A, Almansa R et al. Beneficial role of endogenous immunoglobulin subclasses and isotypes in septic shock. J Crit Care 2012; 27: 616-22.
8. Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M. Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care 2012; 16: 206.
9. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine. 1992. Chest 2009; 136: e28.
10. Giamarellos-Bourboulis EJ, Apostolidou E, Lada M et al. Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome. Crit Care 2013; 17: R247.
11. Rose ME, Lang DM. Evaluating and managing hypogammaglobulinemia. Cleve Clin J Med 2006; 73: 133-7, 140, 143-4.
12. Pan Q, Hammarström L. Molecular basis of IgG subclass deficiency. Immunol Rev 2000; 178: 99-110.
13. Monneret G, Venet F, Kullberg B-J, Netea MG. ICU-acquired immunosuppression and the risk for secondary fungal infections. Med Mycol 2011; 49(Suppl. 1): S17-23.
14. Andaluz-Ojeda D, Iglesias V, Bobillo F et al. Early levels in blood of immunoglobulin M and natural killer cells predict outcome in nonseptic critically ill patients. J Crit Care 2013; 28: 1110.e7-e10.
15. Blaese RM. IgG subclass deficiency and specific antibody deficiency. Patient & Family Handbook for Primary Immunodeficiency Diseases Immune Deficiency Foundation. 51st-3rd ed. Towson MD; 2007.
16. Driessen G, van der Burg M. Educational paper. Eur J Pediatr 2011; 170: 693-702.
17. Alejandria MM, Lansang MAD, Dans LF, Mantaring Iii JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013; 9: CD001090.
18. Neilson AR, Burchardi H, Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock. J Crit Care 2005; 20: 239-49.
19. Norrby-Teglund A, Haque KN, Hammarström L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med 2006; 260: 509-16.
20. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007; 35: 2677-85.